Supplementary Figures 1-2, Supplementary Table 1 from Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figures 1-2, Supplementary Table 1. Supplementary Figure 1: Highthroughput Matrix For H9 and HH. Highthroughput screen was used to determine the synergistic interaction in vitro in H9 and HH T-cell lines. (A) Depicts the observed percent of inhibition matrix following 48 hours of treatment with romidepsin and pralatrexate. Romidepsin concentration is labelled on the y-axis in μM while the pralatrexate concentration if labelled on the x-axis in μM. (B) Depicts the observed percent of inhibition matrix following 72 hours of treatment with romidepsin and pralatrexate. Supplementary Figure 2. Generation of stable mCherryLuciferase expressing H9 and HuT-78 cell line by FACS sorting. Flow cytometric analysis for mCherry expression in H9 control cells (A), in stably transduced H9 cells transfected with the pGLCherryLuciferase plasmid and enriched by FACS (B), in HuT-78 control cells (C), in stably transduced HuT-78 cells transfected with the pGLCherryLuciferase plasmid and enriched by FACS (D). Supplementary Table 1: Forward and reverse primer sequences are listed for all genes evaluated by qPCR.
Authors: Salvia Jain, Xavier Jirau-Serrano, Kelly M. Zullo, Luigi Scotto, Carmine F. Palermo, Stephen A. Sastra, Kenneth P. Olive, Serge Cremers, Tiffany Thomas, Ying Wei, Yuan Zhang, Govind Bhagat, Jennifer E. Amengual, Changchun Deng, Charles Karan, Ronald Realubit, Susan E. Bates, Owen A. O'Connor
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361884763